GlobalData analysed the number of clinical trials examining checkpoint inhibitor targets with start dates between January 1, 2010 and January 21, 2019. Clinical trials that investigate checkpoint inhibitor targets are pivotal for the development of cancer immunotherapies that target specific mechanisms.

The activation or inactivation of certain pathways allows for the termination of cancerous cells. Research from pre-clinical and clinical studies has shown that checkpoint inhibition can be a crucial aspect of tumour immune evasion and systemic immune suppression.

A number of clinical trials conducted on inhibitor targets seem to focus on the programmed cell death protein-1 (PD1) and programmed death-ligand 1 (PDL-1). Over the past five years, there has been a major advancement with the development of checkpoint inhibitors, with the majority of antibodies that are being studied targeting PD-1.

Overall, PD-1 had a higher percentage of clinical trials, with 62.0%, compared to the total trials for PDL-1 (23.5%) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (18.9%), as seen in Figure 1. PD-1, PDL-1, and CTLA-4, stand out as the most valuable therapeutic targets based on the percentage of clinical trials for each target. This is due to the success of drug inhibitors targeting these checkpoints. A significant proportion of clinical trials conducted for the three targets were in Phase II (61.4%), with the majority of these trials being led by non-industry sponsors (56.6%). The US conducted 52.0% of the trials.

In 2011, Bristol-Myers Squibb’s Yervoy (ipilimumab) was approved by the FDA for targeting CTLA-4. In 2014, Merck’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab) received FDA approval for targeting PD-1. In 2016, the FDA approved Genentech’s Tecentriq (atezolizumab) for targeting PDL-1.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.